1. Introduction {#sec1}
===============

Despite significant treatment advancements, lung cancer remains the leading cause of cancer-related mortality worldwide with non-small-cell lung cancer (NSCLC) accounting for 85% of all lung cancer cases \[[@B1], [@B2]\]. Currently, lung adenocarcinoma and squamous cell lung cancer (SCC) are the two most commonly diagnosed forms of NSCLC. Due to the use of low-dose computed tomography (LDCT) in high-risk and some healthy subjects, it has become easier to detect the disease during its early stages when treatment is most effective \[[@B3]\]. Despite dramatic improvements in diagnosing lung cancer, the 5-year cumulative survival rate for NSCLC has remained unchanged at 18.5%. However, most studies have assessed the overall survival (OS) in patients with advanced-stage NSCLC, as only a limited number of patients were diagnosed with the early-stage disease in the past \[[@B4]\]. Nevertheless, some patients with the early-stage NSCLC present with aggressive characteristics, and there is limited information on how to estimate the survival of these patients. Currently, a limited number of studies have used mathematical models to predict the survival outcomes of patients with early-stage NSCLC \[[@B5], [@B6]\]. The development of prognostic models may aid clinicians during treatment planning and patient stratification in the future.

While several prognostic biomarkers have been investigated in lung cancer, there have been limited imaging agents that have advanced to clinical trials. For example, preoperational or initial peripheral blood carcinoembryonic antigen (CEA) levels were previously shown to be useful prognostic biomarkers for NSCLC patients \[[@B7], [@B8]\]. In addition, some immunohistochemical (IHC) markers, such as p53 and Ki-67, have been successfully used for predicting the prognosis of NSCLC patients \[[@B9], [@B10]\]. Patients with a mutated epidermal growth factor receptor (EGFR) were also shown to benefit from specific molecular-targeted therapies \[[@B11]\]. However, the prognostic role of EGFR-targeted agents in NSCLC patients with a pathological tumor size less than 30 mm remains unclear. The new substaging system defined in the 8th edition of the American Joint Committee on Cancer (AJCC) divides stage IA into IA1, IA2, and IA3, which has shown a significant prognostic value for patients with NSCLC \[[@B12]\]. In addition, other prognostic factors may be used in NSCLC patients with a pathological tumor size less than 30 mm, such as smoking status, histopathology subtype, and lymph node metastasis \[[@B13]\]. The combined prognostic factors based on a cohort may aid in the precise assessment of the disease prognosis in NSCLC patients. Recently, several studies have shown that nomogram models can be superior to the traditional TNM staging system for the prediction of patient outcomes in several types of cancer \[[@B14]--[@B16]\]. Nomograms can be used to present an intuitive graph of the results from the statistical predictive model, which makes it possible to quantify the prognostic probability for predicting clinical events individually for each patient.

Therefore, the goal of this study was to develop and validate an available nomogram model by combining clinicopathological variables and molecular biomarkers based on the data obtained from NSCLC patients with a pathological tumor size less than 30 mm from the eastern islands of China. We also sought to compare the prognostic value of a nomogram model with the newest TNM staging system.

2. Material and Methods {#sec2}
=======================

2.1. Patient Population {#sec2.1}
-----------------------

Data were collected from patients treated in the Lung Cancer Research Center of Zhoushan Hospital, Zhejiang Province, China, from January 2007 to December 2017. Since 2007, all patients who underwent surgery with a pathological diagnosis of primary lung cancer were in the database and contacted for follow-up. In total, 786 of the 2434 patients in the database met the inclusion criteria for this study. Tumors that were histologically classified prior to 2011 were reassessed and classified by two senior pathologists in accordance with the World Health Organization Classification and Lung Adenocarcinoma Subtypes followed by the New International Association for the Study of Lung Cancer and the American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS) \[[@B17]\]. The staging was determined following the new substage guidelines found in the 8th edition of the AJCC \[[@B12]\].

Demographic data, including age, sex, history of tobacco exposure, and pathology, which includes histological type, pathological tumor size, lymph node metastasis, tumor location, and pleural invasion, were obtained. In addition, the type of surgical intervention and pathological TNM stage were included. Other factors, such as preoperational peripheral CEA, IHC markers for p53 and Ki-67 expression, and EGFR mutations, were also included. Follow-up data were obtained from the death registration system of the Zhoushan Center for Disease Control and Prevention, along with the medical review of all patients on an outpatient basis with computed tomography (CT) imaging at 3-month intervals for the first year after treatment and then at 6-month intervals.

The exclusion criteria for this study included patients with tumor sizes greater than 30 mm in diameter, small-cell lung cancer (SCLC) cases, large-cell lung cancer (LCLC) cases, lymphoepithelioma-like carcinoma, and neuroendocrine tumors that were 30 mm in diameter or less. Finally, 786 patients were identified to be in this study cohort and separated into the training or validation sets according to their date of surgery. The 457 patients who underwent surgery from 2007 to 2014 were assigned to the training group and used to develop the nomogram prognostic model, while the other 329 patients who underwent surgery from 2015 to 2017 were used to validate the nomogram model. The last follow-up was the date of death or until April 30, 2018, for patients who are still alive. The OS was calculated from the time of surgery until the time of death or the final follow-up. This study was approved by the Ethical Review Committee of Zhoushan Hospital, Zhejiang Province, China. Written content was waived by the Institutional Review Board due to the retrospective nature of this study.

2.2. Statistical Analysis {#sec2.2}
-------------------------

Continuous data were reported as median values with interquartile range. Cumulative survival curves were depicted using the Kaplan-Meier method with a calculated median survival time and a 95% confidence interval (CI). The log-rank test was used to compare the prognostic factors, and the univariate analysis was used to calculate the *P* values. Those *P* values of ≤0.05 were considered statistically significant and used in the multivariate analysis for the Cox proportional hazards regression model. The development of a nomogram for the training set was constructed based on the results of the multivariate analysis using the backward stepwise selection method with the Akaike information criterion (AIC) \[[@B18]\]. The nomogram model was subjected to the internal data validation, and the concordance index (C-index) was calculated to evaluate the predictive accuracy of OS. A larger C-index indicated a more accurate probability to distinguish the outcome of the model. The calibration was estimated using a calibration curve for 1-year, 3-year, and 5-year OS after bias correction.

All statistical analyses were performed using SPSS 22.0 (IBM, Chicago, IL, USA) and R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). *P* values that were ≤0.05 were considered statistically significant with a two-sided test.

3. Results {#sec3}
==========

3.1. Characteristics of Patients in the Training and Validation Cohorts {#sec3.1}
-----------------------------------------------------------------------

A total of 786 cases were identified as having NSCLC with a pathological tumor size less than 30 mm and were separated into the training set (*n* = 457) and validation set (*n* = 329) based on the surgical date. The demographic data and clinicopathological characteristics of the two groups are summarized in [Table 1](#tab1){ref-type="table"}. Among the variables, preoperative serum CEA levels, Ki-67 expression levels, p53 expression levels, and EGFR mutation information were missing in 0.2%, 37.2%, 37.2%, and 41.4% of the cases in the training set and 0.3%, 14.6%, 14.0%, and 0.6% of the cases in the validation set, respectively. The median follow-up intervals were 49 months (range 3-136 months) for the training set and 31 months (range 6-39 months) for the validation set.

3.2. Univariate and Multivariate Analyses of the OS in the Training Set {#sec3.2}
-----------------------------------------------------------------------

The findings from the univariate and multivariate analyses of OS are described in [Table 2](#tab2){ref-type="table"}. The univariate analysis indicated that patients who were female (vs. male, *P* \< 0.001), less than 60 years of age (vs. ≥60 years of age, *P* = 0.004), and nonsmokers (vs. current smokers or those with history of smoking, *P* \< 0.001) and had preoperative CEA levels of less than 5.0 ng/mL (vs. ≥5.0, *P* \< 0.001) showed better OS.

In histology, patients with NSCLC-subtype adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) had more favorable OS than those patients with IAC or SCC (*P* \< 0.001). A pathological tumor size ≤ 10 mm displayed the most favorable OS, followed by a pathological tumor size of 10-20 mm, while larger tumors (20-30 mm) showed the least favorable OS (*P* \< 0.001). Patients with no lymph node metastasis showed superior survival than those patients with lymph node metastasis (N1 or N2, *P* \< 0.001). For the pathological TNM stage, patients with early-stage disease showed better OS than those with advanced-stage disease (*P* \< 0.001). Moreover, patients positive for P53 or Ki-67 expression experienced less favorable OS when compared with those patients negative for P53 (*P* \< 0.001) and Ki-67 (*P* \< 0.001). However, the surgical procedure had no significant impact on OS between the two groups (*P* = 0.850), as well as EGFR mutation status. However, patients with a mutant EGFR showed worse OS than patients with the wild-type EGFR, yet this finding was not statistically significant (*P* = 0.083). All significant factors identified as predictors of OS in the univariate analysis were used for the multivariate analysis based on the Cox proportional hazards regression. The results described that pathological tumor size (*P* \< 0.001), lymph node metastasis (*P* \< 0.001), and Ki-67 expression (*P* \< 0.001) were the independent prognostic factors in the Cox model.

3.3. Development of a Nomogram Model for OS {#sec3.3}
-------------------------------------------

The nomogram model was established using the independent significant prognostic factors ([Figure 1](#fig1){ref-type="fig"}). The nomogram illustrated the points of each predictor ranging from 0 to 100. The results showed that pathological tumor size was the most significant contributor to the prognosis, followed by Ki-67 expression levels and lymph node metastasis. The total scores were calculated and located on the total point scale. The probabilities of OS at 1 year, 3 years, and 5 years posttreatment were individually estimated by drawing a straight line and ranged from 0.80 to 0.98, 0.50 to 0.95, and 0.35 to 0.95, respectively.

3.4. Calibration and Validation of the Nomogram in the Validation Set {#sec3.4}
---------------------------------------------------------------------

The calibration plot presented an optimal prediction for 1-year, 3-year, and 5-year OS between the nomogram prediction and actual observations ([Figure 2](#fig2){ref-type="fig"}). In the validation cohort, the calibration curve also showed an accordant agreement for 1 year and 3 years OS ([Figure 3](#fig3){ref-type="fig"}). Harrell\'s C-index, which was used to evaluate the performance of the constructed nomogram, was 0.856 (95% CI: 0.804-0.908) in the training set and 0.820 in the validation set (95% CI: 0.647-0.993). The TNM staging was 0.814 (95% CI: 0.742-0.886, *P* = 5.280221*e* − 13) in the training set and 0.812 (95% CI: 0.711-0.913, *P* = 0.675) in the validation set.

3.5. Stratifying the Risk Ability of the Prognostic Nomogram Model {#sec3.5}
------------------------------------------------------------------

We divided patients into four risk groups (scores: 0-9.72, 9.72-17.67, 17.67-22.67, and ≥22.67) with the optimal cut-off values for total points in the training set ([Table 3](#tab3){ref-type="table"}). A survival analysis demonstrated that the subgroups showed significant distinctions within the training cohort (*P* \< 0.001, [Figure 4(a)](#fig4){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}). The same cut-off values were also applied to the validation set, and survival differences were represented among the subgroups (*P* \< 0.001, [Figure 4(a)](#fig4){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

In recent years, the increased usage of CT screening has led to an increase in the number of lung cancers with a pathological tumor size less than 30 mm being detected in the clinic \[[@B19], [@B20]\]. However, the prognostic prediction capabilities of a nomogram model have not been constructed for NSCLC patients with a pathological tumor size less than 30 mm. In this study, we developed a nomogram model and internally validated it to predict the prognosis of NSCLC patients from a single institution in the eastern islands of China. This nomogram was not only based on demographic data and clinicopathological characteristics but also focused on the molecular factors and IHC markers. We proposed that the nomogram could allow for better treatment planning in the future.

A nomogram model established on the data from multiple institutions often yields higher accuracy and less bias. However, the nomogram model in this study used data derived from a single institution. In addition, molecular marker data were included in this study. As a vital tumor suppressor, p53 expression is often lost in tumors, which can be directly correlated with the prognosis of patients \[[@B21]\]. Ki-67 is a marker of cell proliferation in NSCLC, and elevated Ki-67 levels have been correlated with poor outcomes in NSCLC patients \[[@B9]\]. Moreover, an *EGFR* mutation was previously discovered to have a prognostic role in NSCLC patients. Our univariate analysis revealed that patients positive for p53 or Ki-67 expression showed less favorable outcomes than those patients who were negative for p53 or Ki-67 in the training cohort. However, the *EGFR* mutation status had no significant effect on the outcome of NSCLC patients. In general, these findings agreed with the results from other studies \[[@B10], [@B22]\]. In addition, sex, age, smoking status, preoperational CEA levels, histology, pathological T categories, lymph node metastasis, and pathological TNM stage were also found to be prognostic factors in the univariable analysis. Through the subsequent multivariable analysis, the pathological T stage and N category, as well as Ki-67 expression, were identified as independent prognostic predictors. Previous studies also demonstrated that tumor size and lymph node metastasis were risk factors for NSCLC \[[@B4], [@B23]\]. Notably, Ki-67 expression was found to be associated with poorer survival outcomes in NSCLC patients. To our knowledge, this is the first attempt to include an IHC marker into a nomogram model.

The nomogram model showed a clear distinction capacity for predicting patient outcomes in the training cohort. The C-index of this model was 0.856, higher than those previously reported in published studies \[[@B23], [@B24]\]. Moreover, the nomogram model was more successfully applied than the AJCC TNM staging classification system in the individual evaluation of patient prognosis, which may be attributed to the inclusion of Ki-67 expression data. IHC markers can provide valuable insight into the pathology of NSCLC, and molecular markers are commonly used in the pathological diagnosis of lung cancer in the clinic \[[@B25]\]. We used molecular markers to build our nomogram model, aiming to increase its overall accuracy. In addition, a relatively good calibration was observed in the nomogram of the training cohort. To validate the nomogram model, we use internal validation data to evaluate the accuracy and calibrate the model. The C-index reflected a good discrimination power in the validation data, but it was lower than that of the training set. This might be due to the shorter follow-up times for patients in the validation cohort. Moreover, using an optimal cut-off value, the nomogram showed excellent prediction capabilities in terms of OS in different risk subgroups. The proposed nomogram may have a potential role in clinically evaluating the OS probability of patients with NSCLC \[[@B26]\].

There were several limitations to this study. The first limitation was the amount of missing data in the training data, such as Ki-67 and p53 expression levels and *EGFR* mutation status. This might introduce selection bias into the nomogram model. The second limitation is that this study was conducted at a single institution and the established nomogram was validated using an internal cohort. External validation based on a larger number of patients at multiple institutions should be introduced in the future. The third limitation was the retrospective nature of this study that had shorter follow-ups, especially in the validation set. Lastly, the fourth limitation was our inability to include some recognized prognostic parameters, such as comorbidity and postoperative complications in the nomogram. Other parameters were not assessed in this study, such as treatment efficacy, disease-free interval, or progression-free survival. In future studies, we will improve the model by using multi-institutional data with longer follow-up times, less missing data, and the presence of other predictive factors.

In the present study, we developed a prognostic nomogram model for NSCLC patients with a pathological tumor size less than 30 mm and validated the model using an internal cohort. We also built proportional OS subgroups in the model to discriminate between different patient outcomes. We developed a high-performance nomogram model that includes molecular marker data and displays a C-index of 0.856. This nomogram could be used as a convenient and precise outcome predictive tool for clinicians in the future, yet further external validations using data from multiple institutions should be considered.

This research was supported, in part, by grants from the Natural Science Foundation of Zhejiang Province, China (No. LQ17H160001), and the Medical Bureau of Zhejiang Province, China (Nos. 2015ZDA032 and 2016RCB020) to WYZ and HBL, from the Science and Technology Bureau of Zhoushan to WYZ (No. 2011C12040), and from the funding of Health High Level Talents of Zhejiang Province and Lung Cancer Center of Zhejiang Province.

Data Availability
=================

The data used to support the findings of this study are available from the corresponding authors upon request.

Disclosure
==========

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest
=====================

The authors have declared that there are no conflicts of interest.

![The prognostic nomogram for NSCLC patients with a pathological tumor size of 30 mm or smaller in the training set. Tumor size: pathological tumor size; LN: lymph node metastasis.](DM2019-8435893.001){#fig1}

![Calibration curves for the prediction of overall survival (OS) in NSCLC patients with a pathological tumor size of 30 mm or smaller in the training cohort. The *x*-axis represents the nomogram-predicted patient survival, while the *y*-axis represents the observed OS at (a) 1 year, (b) 3 years, and (c) 5 years.](DM2019-8435893.002){#fig2}

![Calibration curves for the prediction of overall survival (OS) in NSCLC patients with a pathological tumor size of 30 mm or smaller in the validation cohort. The *x*-axis represents the nomogram-predicted patient survival, while the *y*-axis represents the observed OS at (a) 1 year and (b) 3 years.](DM2019-8435893.003){#fig3}

![Kaplan-Meier curves of overall survival (OS) for the (a) training set and (b) validation set in T1 NSCLC patients separated by nomogram scores.](DM2019-8435893.004){#fig4}

###### 

The overall survival of the training set and validation set in NSCLC patients with a pathological tumor size less than 30 mm.

  Patient characteristics                          Training set (*n* = 457)   Validation set (*n* = 329)                                                               
  ------------------------------------------------ -------------------------- ---------------------------- ------- ------------- ------------------ ----------- ------ -----------
  Sex                                                                                                                                                                  
   Male                                            193                        42.2                         92.7    85.3-100.0    113                34.3        38.0   37.1-38.9
   Female                                          264                        57.8                         117.4   111.5-123.2   216                65.7        38.8   38.5-39.1
  Age (y), median (IQR)                            60 (52-66)                                                                    57 (51-65)                            
   \<60                                            223                        48.8                         114.8   108.4-121.2   186                56.5        38.5   38.0-39.0
   ≥60                                             234                        51.2                         100.8   93.8-107.8    143                43.5        38.5   38.2-38.9
  Smoking                                                                                                                                                              
   Never smoker                                    315                        68.9                         114.1   108.4-119.7   258                78.4        38.8   38.6-39.1
   Current/former smoker                           142                        31.1                         91.8    83.4-100.1    71                 21.6        37.4   38.6-39.1
  Preoperational CEA level (ng/mL), median (IQR)   1.95 (1.28-3.27)           *n* = 456                                          1.75 (1.14-2.79)   *n* = 328          
   \<5.0                                           395                        86.6                         108.7   103.9-113.4   297                90.5        38.7   38.4-39.0
   ≥5.0                                            61                         13.4                         82.3    68.4-96.2     31                 9.5         35.8   33.2-38.3
  Type of surgery                                                                                                                                                      
   Lobectomy                                       383                        83.8                         107.4   102.2-112.5   127                38.6        38.7   38.4-39.1
   Limited resection                               74                         16.2                         91.4    78.5-104.3    202                61.4        38.2   37.4-38.9
  Tumor location                                                                                                                                                       
   Right upper lobe                                161                        35.2                         110.1   102.6-117.6   118                35.9        NA     
   Right middle lobe                               35                         7.7                          117.3   102.0-132.6   34                 10.3               
   Right lower lobe                                68                         14.9                         87.6    75.5-99.6     56                 17.0               
   Left upper lobe                                 124                        27.1                         114.1   104.4-123.9   88                 26.8               
   Left lower lobe                                 58                         12.7                         97.4    85.0-109.8    31                 9.4                
   Undefined                                       11                         2.4                          72.9    43.5-102.2    2                  0.6                
  Histology                                                                                                                                                            
   AIS & MIA                                       195                        42.7                         127.6   124.8-130.4   195                59.3        38.9   38.8-39.1
   IAC                                             198                        43.3                         97.6    89.8-105.4    123                37.4        38.0   37.1-38.9
   SCC                                             64                         14.0                         73.6    62.4-84.8     11                 3.3         33.2   31.7-34.7
  Pathological tumor size (mm), median (IQR)       15 (9-20)                                                                                                           
   ≤10 mm                                          156                        34.1                         126.0   121.5-130.5   180                54.7        38.9   38.8-39.1
   \>10-20 mm                                      196                        42.9                         107.3   100.6-114.1   106                32.2        38.3   37.5-39.1
   \>20-30 mm                                      105                        23.0                         81.3    71.1-91.5     43                 13.1        37.5   35.8-39.1
  Lymph node metastasis                                                                                                                                                
   N0                                              402                        88.0                         114.1   109.3-119.0   311                94.5        38.8   38.5-39.1
   N1                                              23                         5.0                          65.2    45.9-84.6     5                  1.5         26.9   21.5-32.3
   N2                                              32                         7.0                          54.4    62.4-84.8     13                 4.0         34.2   31.1-37.3
  Pathological TNM stage                                                                                                                                               
   0                                               111                        24.4                         128.7   126.1-131.2   99                 30.1        NA     
   IA1                                             77                         16.8                         110.9   100.1-121.7   92                 28.0               
   IA2                                             138                        30.2                         105.5   96.8-114.1    89                 27.0               
   IA3                                             77                         16.8                         91.8    79.7-104.0    31                 9.4                
   IIB                                             23                         5.0                          65.2    45.9-84.6     5                  1.5                
   IIIA                                            31                         6.8                          54.8    42.1-67.5     13                 4.0                
  P53 expression                                   *n* = 287                                                                     *n* = 281                             
   Negative                                        208                        72.5                         83.3    80.7-85.9     211                75.1        38.8   38.5-39.1
   Positive                                        79                         27.5                         68.2    61.2-75.2     70                 24.9        36.5   35.2-37.7
  Ki-67 expression                                 *n* = 287                                                                     *n* = 283                             
   \<10%                                           203                        70.7                         84.2    81.4-87.1     186                65.7        38.9   38.7-39.1
   ≥10%                                            84                         29.3                         67.6    61.2-74.0     97                 34.3        37.6   36.5-38.7
  EGFR mutation                                    *n* = 268                                                                     *n* = 327                             
   Wild type                                       190                        70.9                         76.9    74.8-78.9     182                55.7        38.3   37.7-38.9
   Mutation                                        78                         29.1                         71.4    64.7-78.0     145                44.3        38.8   38.4-39.2

IQR: interquartile range; CEA: carcinoembryonic antigen; AIS: adenocarcinoma *in situ*; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma; SCC: squamous cell lung cancer; EGFR: epidermal growth factor receptor.

###### 

Univariable analysis and Cox proportional hazards regression analysis.

  Variable                           Univariable analysis   Multivariable analysis                                               
  ---------------------------------- ---------------------- ------------------------ ------------ ----------- ------------------ ----------
  Sex                                                                                \<0.001^∗^                                  
   Female                            Reference                                                                                   
   Male                              2.833                  1.865 to 4.304                                                       
  Age (y), median (IQR)                                                              0.004^∗^                                    
   \<60                              Reference                                                                                   
   ≥60                               1.849                  1.221 to 2.799                                                       
  Smoking status                                                                     \<0.001^∗^                                  
   Never smoker                      Reference                                                                                   
   Current/former smoker             2.394                  1.612 to 3.556                                                       
  Preoperational CEA level (ng/mL)                                                   \<0.001^∗^                                  
   \<5.0                             Reference                                                                                   
   ≥5.0                              2.801                  1.807 to 4.342                                                       
  Type of surgery                                                                    0.850                                       
   Lobectomy                         Reference                                                                                   
   Limited resection                 1.058                  0.588 to 1.906                                                       
  Histology                                                                          \<0.001^∗^                                  
   AIS & MIA                         Reference                                                                                   
   IAC                               21.102                 6.614 to 67.326          \<0.001^∗^                                  
   SCC                               40.946                 12.621 to 132.841        \<0.001^∗^                                  
  Pathological tumor size (mm)                                                       \<0.001^∗^                                  0.011^∗^
   ≤10 mm                            Reference                                                    Reference                      
   10-20 mm                          10.548                 3.278 to 33.947          \<0.001^∗^   6.280       0.783 to 50.367    0.084
   \>20-30 mm                        25.350                 7.904 to 81.311          \<0.001^∗^   13.831      1.711 to 111.823   0.014^∗^
  Lymph node metastasis                                                              \<0.001^∗^                                  0.037^∗^
   N0                                Reference                                                    Reference                      
   N1                                4.689                  2.522 to 8.718           \<0.001^∗^   2.606       0.964 to 7.049     0.059
   N2                                6.849                  4.270 to 10.985          \<0.001^∗^   2.970       1.170 to 7.539     0.022^∗^
  Pathological TNM stage                                                             \<0.001^∗^                                  
   0                                 Reference                                                                                   
   IA1                               7.007                  0.726 to 67.588          0.092                                       
   IA2                               30.748                 4.192 to 225.536         0.001^∗^                                    
   IA3                               53.342                 7.260 to 391.918         \<0.001^∗^                                  
   IIB                               99.073                 12.857 to 763.431        \<0.001^∗^                                  
   IIIA                              142.128                19.164 to 1054.090       \<0.001^∗^                                  
  P53 expression                                                                     \<0.001^∗^                                  
   Negative                          Reference                                                                                   
   Positive                          5.217                  2.577 to 10.564                                                      
  Ki-67 expression                                                                   \<0.001^∗^                                  0.025^∗^
   \<10%                             Reference                                                    Reference                      
   ≥10%                              8.412                  3.632 to 19.486                       2.954        1.146 to 7.614    
  EGFR mutation                                                                      0.083                                       
   Wild type                         Reference                                                                                   
   Mutation                          2.336                  0.895 to 6.098                                                       

IQR: interquartile range; CEA: carcinoembryonic antigen; AIS: adenocarcinoma *in situ*; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma; SCC: squamous cell lung cancer; EGFR: epidermal growth factor receptor. ^∗^*P* \< 0.05.

###### 

Point assignment, prognostic scores, and estimated 5-year overall survival based on pathological tumor size, lymph node metastasis, and Ki-67 expression.

  Variable                       Prognostic score   Estimated 5-year overall survival (%)
  ------------------------------ ------------------ ---------------------------------------
  Pathological tumor size (mm)                      
   ≤10 mm                        10                 
   10-20 mm                      5                  
   \>20-30 mm                    0                  
  Lymph node metastasis                             
   N0                            4.72               
   N1                            2.36               
   N2                            0                  
  Ki-67 protein expression                          
   \<10%                         7.95               
   ≥10%                          0                  
  Total prognostic score (IQR)                      
   0-9.72                                           57.8
   9.72-17.67                                       85.3
   7.67-22.67                                       97.2
   ≥22.67                                           100

IQR: interquartile range.

###### 

Kaplan-Meier survival analysis of nomogram score groups for the training and validation sets.

  Group            0-9.72 (*P* value)   9.72-17.67 (*P* value)   17.67-22.67 (*P* value)   ≥22.67 (*P* value)
  ---------------- -------------------- ------------------------ ------------------------- --------------------
  Training set                                                                             
   0-9.72          ---                  0.022                    \<0.001                   \<0.001
   9.72-17.67      0.022                ---                      0.007                     0.001
   17.67-22.67     \<0.001              0.007                    ---                       0.569
   ≥22.67          \<0.001              0.001                    0.569                     ---
  Validation set                                                                           
   0-9.72          ---                  0.067                    0.013                     0.001
   9.72-17.67      0.067                ---                      0.106                     0.072
   17.67-22.67     0.013                0.106                    ---                       0.512
   ≥22.67          0.001                0.072                    0.512                     ---

[^1]: Academic Editor: Kishore Chaudhry
